Sunday May 26, 2019
Home Business Harish Hande:...

Harish Hande: India makes development and sustainable energy go hand in hand

0
//
Image source: indiaconferenceatharvard.com

Kolkata: The Ramon Magsaysay recipient and social entrepreneur Harish Hande on Saturday emphasized on the need to conduct on-field researches instead of publishing them on papers. Hande believes that India’s ability to prove development and sustainable energy solutions can go hand in hand.

“We need to come up with a research culture where research is linked to the field. Today research is linked to paper. Professors are into publishing more papers. How many of your innovations have actually happened on the field? We should be benchmarked on that,” Hande said in an interaction with media persons here.

Recognised for his efforts to put solar power technology in the hands of the poor, Hande, an IIT-Kharagpur alumnus, lamented the gap in tapping into the regional rural banking sector.

“What India has which many developing countries do not have is the fantastic infrastructure of financial institutions in the rural area. Somewhere it will be efficient, somewhere not,” he said on the sidelines of the Innovation 2016 conference here organised by business chamber CII.

Hande highlighted the need to “piggyback” on the RRBs and ITIs (Industrial Training Institutes) to trigger an energy revolution.

About energy, finance and market linkage, the founder of Solar Electric Light Company (SELCO) India stressed on the need for the country to adopt an aggressive stance in international negotiations.

“It is the only country which can create innovations where it can prove development and sustainable energy can go hand in hand without sacrificing each other. India should (rather than being defensive saying the West has been polluting) be aggressive and say we are innovative, we can show how poverty can be removed in a sustainable way,” Hande added. (IANS)

Next Story

Scientists Facilitate The Regulatory Process For Herbal Drugs

A 2017 report by the Confederation of Indian Industry (CII) predicts that the biosimilars market in India, that is currently worth about Rs 15,000 crore, is expected to cross the staggering Rs 2,50,000 crore-mark by 2030.

0
drugs
Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export. Pixabay

Council of Scientific and Industrial Research’s constituent laboratory, the Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, and the Indian Pharmacopeia Commission (IPC), Ghaziabad, have joined hands to facilitate the regulatory process for biosimilars and herbal drugs, as per a statement here on Sunday.

The scope of the memorandum of understanding (MoU) signed between CSIR-CCMB and the IPC is the development of biopharmaceutical reference standards and impurities therein, development of monographs for important Monoclonal Antibodies and identification of herbal drugs based on DNA Barcode analysis, a CCMB statement said.

Use of biologics – biological products that function as drugs against diseases – also known as biosimilars, are expanding their presence rapidly in the healthcare sector, including in India.

lab

Scientific validation and characterization of herbal drugs will not only help authentication of such drugs but also will bring credibility for this industry, the CCMB added. Pixabay

A 2017 report by the Confederation of Indian Industry (CII) predicts that the biosimilars market in India, that is currently worth about Rs 15,000 crore, is expected to cross the staggering Rs 2,50,000 crore-mark by 2030.

Emergence of biopharmaceutical drugs as a preferred choice for therapy over conventional pharma drugs, requires concerted efforts by various sectors within the country towards production, characterisation and validation of indigenously developed products, the CCMB said.

The agreement was signed by CSIR-CCMB Director Rakesh Mishra and IPC’s Secretary-cum-Scientific Director G.N. Singh.

This collaboration, which has come into force with immediate effect, is very important in the current scenario owing to the increase in use of therapeutic proteins and herbal drugs for various diseases, the statement said.

scientist
Use of biologics – biological products that function as drugs against diseases – also known as biosimilars, are expanding their presence rapidly in the healthcare sector, including in India. Pixabay

Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export.

Also Read: When You Engage in ‘Hedonic Consumption’? Read Here To Find Out

This collaborative project will be executed at par with pharmacopeia standards of other countries, it said.

Scientific validation and characterization of herbal drugs will not only help authentication of such drugs but also will bring credibility for this industry, the CCMB added. (IANS)